Clinical trials: Metastatic Neoplasm
Breast Cancer
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab.
- Trial name
- NCT00567879
- Testing
- Panobinostat, Trastuzumab
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic…
- Trial name
- NCT00544908
- Testing
- dasatinib, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in…
- Trial name
- NCT03600350
- Testing
- pTVG-HP, Nivolumab, GM-CSF
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Thyroid Cancer
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
The purpose of this study is to find out if the drug AZD6244 can improve the radioactive iodine uptake by the patient's metastatic thyroid cancer.
- Trial name
- NCT00970359
- Testing
- AZD6244
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastasis Spine, Metastasis to Bone
OsteoCool Tumor Ablation Post-Market Study
This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
- Trial name
- OPuS One (NCT03249584)
- Testing
- OsteoCool™ RF Ablation
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 218 people
- Sponsor
- MedtronicNeuro
Gastric Cancer
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate progression-free survival in participants with gastric or gastroesophageal junction cancer who have had disease progression following first-line therapy who undergo treatment with…
- Trial name
- NCT01983878
- Testing
- Ramucirumab
- Where
- 11 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Degenerative Disc Disease, Spondylolisthesis
The European Robotic Spinal Instrumentation (EUROSPIN) Study
In a multinational prospective study, preoperative, intraoperative, perioperative and follow-up data on patients receiving thoracolumbar pedicle screw placement for degenerative disease or infections or tumors will be collected.
- Conditions
- Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis, Recurrent Disc Herniation
- Trial name
- EUROSPIN (NCT03398915)
- Testing
- Transpedicular Instrumentation
- Where
- 12 sites in Austria, France and 5 more
- Volunteers
- 932 people
- Sponsor
- Marc Schröder
Metastatic Pancreatic Cancer
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with…
- Trial name
- NCT01088815
- Testing
- Gemcitabine, nab-Paclitaxel, GDC-0449
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
PhII ICb With/Without Erbitux in MBC Pts
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
- Trial name
- CA225200 (NCT00248287)
- Testing
- Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
- Where
- 59 sites in United States
- Volunteers
- 154 people
- Sponsor
- US Oncology Research
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy…
- Trial name
- NCT04921904
- Testing
- Abemaciclib, Ramucirumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Microsatellite Stable, Mismatch Repair Protein Proficient
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
This phase II trial studies the side effects and best dose of capecitabine when given together with pembrolizumab and bevacizumab, and investigates how well they work in treating patients with microsatellite stable colorectal…
- Conditions
- Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7
- Trial name
- NCT03396926
- Testing
- Bevacizumab, Capecitabine, Specimen collection
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Non-Squamous Non-Small Cell Lung Cancer
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in…
- Trial name
- NCT02596958
- Testing
- Bevacizumab
- Where
- Germany
- Volunteers
- 996 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Metronomic Therapy in Patients With Metastatic Melanoma
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible.
- Trial name
- NCT01542255
- Testing
- vinblastine, Cyclophosphamide, dacarbazine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic…
- Trial name
- NCT01695044
- Testing
- PSMA ADC
- Where
- 36 sites in United States
- Volunteers
- 119 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Pancreatic Neoplasms
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the…
- Trial name
- NCT00637247
- Testing
- imexon in combination with gemcitabine
- Where
- 48 sites in United States
- Volunteers
- 142 people
- Sponsor
- AmpliMed Corporation
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.